{"title": "Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.", "author": "Thiruvengadam; Ramachandran; Awasthi; Amit; Medigeshi; Guruprasad; Bhattacharya; Sankar; Mani; Shailendra; Sivasubbu; Sridhar; Shrivastava; Tripti; Samal; Sweety; Rathna Murugesan; Deepika; Koundinya Desiraju; Bapu; Kshetrapal; Pallavi; Pandey; Rajesh; Scaria; Vinod; Kumar Malik; Praveen; Taneja; Juhi; Binayke; Akshay; Vohra; Tarini; Zaheer; Aymaan; Rathore; Deepak; Ahmad Khan; Naseem; Shaman; Heena; Ahmed; Shubbir; Kumar; Deshpande; Suprit; Subramani; Chandru; Wadhwa; Nitya; Gupta; Nimesh; Anil K; Jayanta; Agrawal; Anurag; Vrati; Sudhanshu; Bhatnagar; Shinjini; Garg", "url": null, "hostname": null, "description": null, "sitename": "Lancet Infect Dis", "date": "2021-04-01", "cleaned_text": "Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis ; 22(4): 473-482, to assess [effectiveness]of the [ChAdOx1 nCoV-19] [vaccine], predominantly against the [delta](B.1.617.2) addition immune a positive RT-PCR test for SARS-CoV-2 infection between April 1, 2021, and May 31, 2021, were included as cases and individuals [who]had a negative RT-PCR test were included as controls after matching with cases on calendar week of RT-PCR test. The primary outcome was [effectiveness]of complete cases of confirmed SARS-CoV-2 infection, 85 (3\u00b76%) were fully vaccinated compared with 168 (8\u00b75%) of 1981 controls (adjusted OR [aOR] 0\u00b737 [95% of 2451 of cases and 181 (9\u00b71%) of 1994) controls had a 31\u00b76-57\u00b77). One of 84 cases with moderate-to-severe COVID-19 was fully vaccinated compared with 84 of 2295 cases with mild COVID-19 (aOR 0\u00b719 with moderate-to-severe COVID-19 had received a [single dose]compared with 153 of 2364 participants with mild [disease](aOR 0\u00b720 [95% CI 0\u00b706-0\u00b754]). Among 49 healthy, fully vaccinated individuals, neutralising [antibody responses]were lower against the alpha COVID-19, a [surge]that was dominated by the highly transmissible [delta]variant of [SARS-CoV-2]. Spike-specific [T-cell]responses were maintained against the cellular compensate for waning [humoral immunity]. FUNDING:Department of [Biotechnology] "}